Journal of Tumor Research
Open Access

Effect of Tumor Cells and Immune System in Human Breast Carcinoma

Chun Zheng^{* *}Correspondence: Chun Zheng, Department of Breast Surgery, Zhejiang University School of Medicine, Hangzhou, China, Email:

Author info »

Description

The main cause of cancer-related deaths in women is breast cancer. Limited understanding of the ecosystems affecting breast cancer is a significant barrier to the application of precision medicine. Cancer cells, invading immune cells, stromal cells, and other cell types, along with non-cellular tissue components, make up tumor ecosystems. Because of genetic and non-genetic origins, cancer cells and tumor-associated cells are phenotypically and functionally heterogeneous. Targets of existing treatments and those in development, such as the ER, HER2, Phosphatidylinositol 3-kinase (PI3K), AKT serine/threonine kinases (AKTs), mammalian target of rapamycin (mTOR), Androgen Receptor (AR), Epidermal Growth Factor Receptor (EGFR), poly (ADP-ribose) polymerase (PARP), BCL-2, Survivin. This heterogeneity provides cancer cells the abilities they need to grow, survive, and invade and is probably what causes variable treatment outcomes. Recent single-cell genomic and transcriptome studies of breast cancer provided insights on intraand intertumor variations in clonal composition and tumor genomic diversity, although only few cells and tumors were examined. The morphologies of luminal and myoepithelial (basal) cells are strictly regulated in a healthy mammary gland. In contrast to basal cells, which only express K5, K14, and Smooth Muscle Actin (SMA), luminal cells heterogeneously express ER, the Progesterone Receptor (PR), and the cytokeratins K7, K8, and K18.

Cellular interactions also influence tumor ecosystems, therefore therapies that aim to disrupt these interactions could be quite effective. Examples include immunosuppressive treatments that target worn-out and regulatory T cells (T-regs). Through the activation of co-inhibitory receptors such PD-1, CTLA-4, and TIM-3, tumor cells, Tumor-Associated Macrophages (TAMs), and stromal cells can cause T cell fatigue. Immunosuppressive cytokines can be released by T-regs. According to ongoing clinical trials, breast cancer patients response rates to checkpoint inhibitor medications do not match those of melanoma or lung cancer patients, most likely due to breast cancer patients lower immunogenicity. However, overall response rates have been noted in cohorts chosen for patients with PD-L1+ breast cancers. TAMs are thus interesting therapeutic targets since they can influence tumor ecosystems either by immunosuppressive activities (such the production of PD-L1) or by fostering tumor growth, angiogenesis, and invasion.

Given the diversity of cell phenotypes and cellular interactions found in breast cancer, it is ideal for patient categorization and treatment to take the entire tumor ecology into consideration. Recent single-cell RNA sequencing studies offered a glimpse into the diversity and ecology of breast cancer immune cell phenotypes, providing the groundwork for studies employing large patient cohorts. But at the moment, ER, PR, HER2, and the proliferation marker Ki-67 expression in tumor cells is used to stratify breast cancers for clinical purposes. The tumors are classified as luminal A (ER+ and/or PR+, HER2, Ki-67+ 20%), luminal B (ER+ and/or PR+, HER2+), luminal B-HER2+ (ER+ and/or PR+, HER2+), HER2+ (ERPRHER2+), and Triple- Negative (TN; ERPRHER2). These biomarkers are utilized for treatment decisions, act as surrogates for prognostic gene expression profiles. Different classification systems based on changes in the genome and gene expression have been developed. In order to determine the prognosis of a patient, pathological tumor grading also evaluates the morphological departure of tumor tissue and cells from normal. Despite the fact that these stratifications have increased the effectiveness of therapy, patient responses differ within each category, necessitating a more thorough characterization of breast cancer ecosystems.

Millions of cells from 144 human breast tumor samples representing all clinical subtypes were subjected to single-cell mass cytometry in this study to clarify the phenotypic variety and immune cell-tumor connections in breast cancer ecosystems. 46 samples that were placed next to tumor tissue (referred to as "juxta-tumoral") and four mammoplasty samples from people who had never had breast cancer made up the non-tumor controls. The results indicated that immune and tumor cells in breast cancer ecosystems exhibit enormous phenotypic variation. Thus established computational scores characterizing tumor phenotypic abnormalities, individuality, and richness in order to measure many elements of tumor heterogeneity. Each tumor ecosystem was made up of different phenotypically aberrant tumor cells, and there were many of tumor cell morphologies that were resistant to treatment. In high-grade ER+ and ER+ cancers, which are normally not associated with immunogenicity. Thus identified tumor and immune cell morphologies and phenotype interactions linked to poor prognosis, immunosuppression, and response to checkpoint inhibitor immunotherapy. The basis for patient classification based on the breast cancer ecosystem is provided by this singlecell atlas.